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Background: Primary human papilloma virus (HPV) screening is more effective than cytology in reducing the risk of
cervical cancer, but screening intervals should be extended in HPV-negative women. However, some Markov
models predicted that long intervals are associated with an excess risk of cervical cancer. The aim of this analysis
was to estimate the real-life risks and benefits of annual Papanicolaou (Pap) screening in HPV-negative women with
normal cytology.
Methods: Women with negative Hybrid Capture 2 (HC2) results and normal cytology at the time of inclusion in the
Hannover HPV screening trial underwent annual Pap smears for 5 years. A subgroup was randomly selected for
retesting with cytology, HC2, and colposcopy 60–68 months after recruitment.
Results: Of 4236 women included, 3406 had at least one Pap smear, but only 1185 attended all five annual
screening visits. The proportion of women with at least one abnormal smear was 14.4% in 60 months. The
probability of abnormal smears increased continuously over time. No case of ≥ CIN2+ was observed during 5 years.
Of 605 women selected for subgroup analysis, 292 agreed to be retested (48.3%). The rate of high-risk HPV at 60–68
months was 3.0% (9/296).
Conclusions: The long-term risk of high-grade neoplasia after an initial negative HC2 test and normal cytology
result was low, while the rate of false-positive abnormal Pap smears was significant and increased constantly over
time. Pap smear screening of HPV-negative women more frequently than every 5 years could be potentially
harmful and seems to be of little clinical value.
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Screening intervalsBackground
There is a high level of evidence that human papilloma
virus (HPV) testing is more effective than cytology in
reducing the risk of CIN3 and cervical cancer and allows
for the extension of screening intervals up to 7 years
[1,2]. Organized screening programs in Italy, Sweden,
the Netherlands, and other countries are being tran-
sitioned from Papanicolaou (Pap) smear-based tests to* Correspondence: k.u.petry@klinikum.wolfsburg.de
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reproduction in any medium, provided the orprimary HPV screening. The American Cancer Society
recommends screening intervals of 5 years for women
with negative high-risk HPV (HR-HPV) results and nor-
mal cytology while for cytology-based screening European
guidelines discourage intervals of less than 3 years [3].
However concerns have been raised that longer intervals
between screening rounds may compromise cervical
cancer prevention. A Markov model, using data from the
USA, estimated that increasing Pap smear screening inter-
vals from 1 to 3 years after the last negative test in women
aged 30–64 years would be associated with an average
excess risk of cervical cancer of approximately 3 in
100,000 [4]. Similarly, a Markov Model for cervical cancerd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of more than 2 years for HPV screening would miss
CIN3 lesions and may result in an excess risk of
cervical cancer [5].
While there is general agreement among experts that
the benefits of short-interval Pap smear testing may be
outweighed by the risks of overdiagnosis, overtreatment
and other kinds of harm, there is limited direct evidence
to support this approach. In a prospective cohort study
including 8466 women in Hannover and Tuebingen,
Germany, we demonstrated that a negative HPV test
result, even in combination with a positive Pap result,
virtually excluded any risk of underlying high-grade
disease [6]. The 5-year follow-up of this study was in-
cluded in the joint European cohort study on the long-
term predictive value of HPV testing and cytology to
detect CIN3 or cancer [7]. However the European multi-
center study did not analyze the frequency of abnormal
screening results during follow-up or the possible corre-
lation with the length of screening intervals. Within the
European multicenter study, the Hannover cohort was
the only sub-study with annual Pap smear follow-up for
HPV-negative women with normal cytology at recruit-
ment. Therefore, we have re-analyzed ‘real-life’ data from
the Hannover cohort study to estimate the risks and bene-
fits of annual Pap screening over 5 years in HPV-negative
women with normal cytology.
Methods
Study population
Between December 1998 and September 2001, women
(age 30 years or older) attending routine cervical cancer
screening were recruited from 15 urban, suburban or
rural, office-based gynecology practices in Hannover and
the surrounding areas. Women were eligible for inclu-
sion in the original trial [6] if they were attending for
routine annual cervical cancer screening, were 30 years
of age or older, had not undergone a hysterectomy, had
no history of atypical cytology, CIN, or treatment for
cervical disease in the preceding year, and were not cur-
rently pregnant. There was no upper age limit, but
94.6% of participants were aged 30–60 years old at re-
cruitment. Written informed consent was obtained from
the patients by the participating gynecologists. The
study was approved by the local ethics committee at the
University of Hannover. Here we report on the follow-
up findings of women who had negative Hybrid Capture
2 (HC2) results and normal Pap smear findings at
recruitment.
Screening examinations and HPV testing
At the first gynecological examination, the cervix was
visualized and a sample was taken for routine cervical
cytology following the procedures normally used in eachgynecological practice. A second sample was then
obtained with a Digene Cervical Sampler (Medscan,
Uppsala, Sweden), and suspended in 1 mL of specimen
transport medium (STM/Digene Inc. Gaithersburg,
MD, USA) for HPV DNA testing. Samples for HPV tes-
ting were stored at 4°C for a maximum of 4 weeks prior
to testing at the University of Hannover. HPV testing
was performed for high-risk types only, using the HC2
test (HR-HC2/Qiagen Inc.) following the manufacturer’s
instructions. Samples were considered positive if they
attained or exceeded the FDA approved threshold of
1.0 pg HPV DNA/mL.Cytological diagnoses
All cervical smears were analyzed at one of eight
cytology laboratories routinely used by each participating
gynecology office. In this study, smears were considered:
a) ‘positive’ if any degree of cytological abnormality was
observed (≥ Pap2w, which is equivalent to atypical
squamous cells of undetermined significance [ASC-US]
in the Bethesda system); b) ‘low-grade squamous intra-
epithelial lesion (LSIL) or more’ if classified as Pap3d
(CIN1 or 2) or more. Pap3d (CIN 1) is equivalent to
LSIL, whereas Pap3d (CIN2) is equivalent to high-grade
squamous intraepithelial lesion (HSIL) in the Bethesda
classification.
The ‘Pap2w’ (W = wiederholen or repeat) is a widely
used category although it is not part of official German
(Munich II) cytology classification [6]. Pap2w is equiva-
lent to ASC-US, and according to national guidelines
needs to be followed by repeat smears or HPV triage [8].
The cytology laboratories had not been informed about
the study and therefore read the smears under routine
screening conditions.Follow-up protocol
Women with negative HPV tests and normal Pap
smear results (double negative) at recruitment were
followed with annual Pap smear screening in private
gynecology offices according to German guidelines.
Pap smear results and all interventions related to cer-
vical disease were reported for inclusion in the cen-
tral study database.
After approximately 5 years’ follow up (50–68 months)
a representative subgroup of women with initially
double-negative test results (every seventh participant)
was invited for colposcopy, Pap smears and HC2 re-
testing. Punch biopsies or endocervical curettage were
performed if appropriate.
The aim of the follow-up subgroup analysis was to de-
termine the proportion of women developing abnormal
cytology and the proportion with HR-HPV infection at
the end of the study.
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The rationale for the selection of every seventh double-
negative participant was based on our previous expe-
rience showing that in the first year of a study only 50%
of such subjects will accept the invitation for repeat
screening. In Germany in women aged 30+ years the
average rate of CIN3+ is 0.3–0.9% and of CIN2+
1.0–1.6% [9], therefore, we calculated that a sample of
300 women was required to estimate risk with sufficient
precision in women with double-negative test results.
For data analysis we used SPSS Statistics version 20
(IBM Corporation, Armonk, NY, USA). The Kaplan-
Meier method was used for survival analysis to deter-
mine the proportions of events of ≥ Pap2w during the
follow-up period [10]. To investigate a potential in-
fluence of womens’ age, we applied a Cox regression
model with age as a nominal covariate with four age
categories of equal size [11].
Results
Findings at enrolment and during follow-up
At enrolment, 4236 of 4737 women had negative HC2
results and normal Pap smear findings, of whom 3406
(80.4%) had at least one further routine Pap smear in
the following 1–6 years. Mean age was 40.8 years
(SD 8.0). In total, 281 women developed an abnormal
cytology, of whom 202 (mean age 40.3 years, SD 7.3)
were diagnosed with ASC-US and 79 (mean age 42.2
years, SD 7.8) with LSIL or more during follow-up.
Kaplan-Meier cumulative 1-minus survival curves
(Figure 1) showed a continuous increase over time for
any positive smear as well as for LSIL or more. During
the 5-year follow-up, 1185 (34.8%) double-negative
participants attended four or more annual Pap smearFigure 1 Kaplan-Meier cumulative 1-minus survival curves
showing the proportion of patients with abnormal cytology
over time.screening rounds in accordance with the German
screening program. The proportion of women with
abnormal Pap smear findings ranged from 2.2–3.5% per
screening round. The cumulative proportion of women
with at least one atypical Pap smear was 14.4% among
those attending all five annual screening visits following
enrolment. There was no significant association bet-
ween women’s age and the cumulative proportion deve-
loping a LSIL or worse lesion (Table 1).
When consulted, we discouraged excisional treatment
for all women with ASC-US and for most LSIL cases be-
cause of the assumed low risk of high-grade cervical
disease. However, 15 patients were transferred for
colposcopy during follow-up, 15 underwent diagnostic
cold-knife conizations and three (aged 42, 51, and 54
years old at the time of the operation) had hysterecto-
mies without colposcopy outside the study protocol be-
cause of persisting abnormal smears. No case of CIN2+
was reported among these 33 women with histological
assessment.
Proportion of abnormal Pap smears, HPV, and CIN at
months 60–68
From 605 women randomly selected from the popula-
tion that tested HC2 negative and showed normal Pap
smears at study entry, 296 (48.9%) agreed to undergo
colposcopy 60–68 months after recruitment (Figure 2).
Of these, 272 (91.9%) women retested negative for HR-
HPV DNA using HC2 and had normal Pap smear
results. In total, 18 women (6.1%) had Pap smears classi-
fied as ASC-US or LSIL, of whom 15 (5.1%) tested nega-
tive for HPV, while three (1.0%) had abnormal cytology
and positive HC2 results. Overall, nine (3.0%) women
had positive HC2 tests. Out of the total cohort of 296
women, 74 (25%) underwent punch biopsies at colpos-
copy, but no case of CIN 2+ was detected.
Discussion
We re-analyzed data from a prospective cohort study to
assess the benefits and harms of short-interval Pap
screening in HPV-negative women. We did not find a
single case of CIN2+ among 296 women who underwent
careful assessment with colposcopy and, if necessary,
biopsies at the end of the study, 60–68 months after
recruitment. Furthermore, no case of CIN2 or more wasTable 1 Association between age (in categories) and
proportion developing a positive smear (≥ ASC-US)
Age group (years) N Odds ratio 95% Confidence intervals
≤ 34 906 Reference
35–39 802 1.28 0.92–1.79
40–46 895 1.26 0.91–1.74







normal cytology at 
enrolment
605 randomly 
selected (every 7th 
participant) for 
substudy
296 agreed to 




272 HC2-negative and 
normal Pap smear
15 HC2-negative and 
atypical Pap smear
9 HC2-positive
6 HC2-positive and 
normal Pap smear
3 HC2-positive and 
atypical Pap smear
Figure 2 Patient disposition and incidence of atypical Pap
smear and positive HC2-tests among 296 women, 60–68
months after recruitment.
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ring Pap smear follow-up, including 33 women with
histological assessment. We conclude that HPV scree-
ning allows early detection of clinically relevant lesions,
and that the incidence of true high-grade lesions is low
among women with a double-negative cotest (cytology
and HPV), although likely to be higher in the routine
setting compared with study conditions.
Our data identify disadvantages of the current annual
Pap smear screening concept in Germany. In partici-
pants who attended annually for all five screening visits,
the risk of having at least one atypical Pap smear result
consistently increased during the second to the fifth
screening rounds. If every participant attended all fiveannual screening rounds (100% attendance), the overall
specificity of the Pap smear screening program would be
less than 86% for CIN2+. However, only approximately
one-third of women attended at least four follow-up
visits. The high rate of participants lost during follow-up
is only partly explained by migration and women failing
to attend routine visits. Another contributing factor is
that women frequently changed their gynecologists and
were lost to follow-up if the new practice was not par-
ticipating in the study. As private practices act as inde-
pendent units, the new practice was usually unaware of
previous screening results. Therefore, we cannot exclude
the possibility that some cases of high-grade neoplasia
may have been missed, but based on the overall follow-
up data, the rate of missed diagnosis seems to be very
low.
In fact, our study protocol may even underestimate
adverse events associated with annual Pap smear tests.
We actively discouraged excisional therapy because we
assumed a very low risk of CIN2+ in the initially HPV-
negative study population and, because we relied com-
pletely on voluntary submission of information about
any kind of invasive procedures, we cannot exclude a
substantial under-reporting of such measures. The prac-
tice of histological assessment of women with atypical
Pap smears with the direct use of cold knife conization
without prior colposcopy is still widespread and adds to
the relatively high cost of cervical cancer screening as
demonstrated in a recent study in Germany [12]. In
addition to cost, several other harmful consequences of
overdiagnosis are recognized including pain, inconve-
nience, anxiety, and procedure-related morbidity [13],
including obstetrical adverse effects [14,15].
Guidelines recommend screening intervals can be safely
extended to 3 years in women aged over 30 years when
HPV and Pap tests are combined [16]. For women aged
30–65 years who want to lengthen the screening interval,
the US Preventive Services Task Force (USPSTF) now
recommends screening with a combination of cytology
and HPV testing every 5 years [17]. Nevertheless, despite
national and international guidelines recommending ex-
tended screening intervals in women with normal cytology
and negative HPV status [18], evidence from the USA has
shown that many physicians are reluctant to change from
annual screening [16,19]. For example, a nationally repre-
sentative survey of practice among office-based providers
and hospital outpatient departments found that most pro-
viders in both settings would continue to perform annual
Pap screening for three different clinical scenarios invol-
ving women aged 30–60 years with normal Pap and nega-
tive HPV test results [16]. Of note, the survey found that
only 14% of office-based providers would recommend a
Pap screening interval of ≥ 3 years for women aged 30–60
years old, with current Pap and HPV-negative results and
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sons suggested for physicians’ resistance to extending
Pap screening intervals include the influence of local
opinion leaders, concern about less frequent visits for
other preventive care examinations, patient preference
for annual screening, and loss of financial incentives
[19]. Concern has also been raised that HPV co-testing
will increase costs unless screening intervals are
extended [19]. It is interesting to note from the US sur-
vey reported by Saraiya et al. that few physicians re-
commended another HPV test after 3 years and many
thought that not performing any HPV test was an accep-
table option [19].
We found a low rate of new HPV infections among
women who were initially tested negative for HR-HPV.
The rate of new infections was just 3.0% based on HC2
results at 60–68 months of follow-up. This makes re-
peated HPV-screening with intervals of every 5 years an
even more attractive option to prevent cervical cancer. It
seems very likely that the HPV-prevalence will be much
lower in subsequent screening rounds compared with
the prevalence found at first recruitment.
Conclusion
In conclusion, in women aged over 30 years with normal
cytology and a negative HPV test result, Pap smear
screening of HPV-negative women more frequently than
every 5 years could be potentially harmful and seems to
be of little clinical value.
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